HOSU-53 (JBZ-001), an orally bioavailable new chemical entity, is a highly potent DHODH inhibitor in late preclinical development for application in cancer therapy, and it recently received investigational new drug (IND) approval for a first-in-human clinical trial [22]. This evidence concerns the gene DHODH and cancer.